Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07422480 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Study acronym: ELRiSE MDS
StatusRecruiting
PhasePhase 3
SponsorTakeda
Started2026-05-21
View on ClinicalTrials.gov ↗
The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion compared with epoetin alfa, the RBC transfusion burden and quality of life compared with epoetin alfa. The study also aims to find out the extent of the immune response to elritercept. The study will also check on the medical problems (safety) of elritercept.

Amendment history 1 change detected by DataLookout

2026-06-16
Trial sites expanded: 146 → 154 locations
Trial Details
NCT Number NCT07422480
Lead Sponsor Takeda
Conditions Myelodysplastic Syndrome, Anemia
Enrollment 300 participants
Start Date 2026-05-21
Primary Completion 2029-04-30 (estimated)
Study Completion 2033-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-22